Director Charlene Barshefsky filed a Form 4 with the SEC on September 10, 2026, disclosing the exercise of stock options and a subsequent sale of Class A Common Stock of Estee Lauder Companies Inc. (NYSE:EL) on September 9, 2026.
Kevin Waters, Executive Vice President and CFO of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on September 10, 2026, disclosing the sale of 373 shares of common stock on September 9, 2026, as part of the company's sell-to-cover process for tax withholding obligations.
Barry L. Templin, Executive Vice President and Chief Technology Officer of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on September 10, 2026, disclosing the sale of 373 shares of common stock on September 9, 2026, in connection with the vesting of restricted stock …
Alaleh Nouri, Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), filed a Form 4 on September 10, 2026, disclosing the sale of 297 shares of common stock on September 9, 2026, in connection with a tax withholding obligation.
Amir Cohen, Chief Accounting Officer of Strata Critical Medical, Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting a transaction dated September 8, 2026.
Louis R. Verdetto, CEO of Clinical Services at Strata Critical Medical, Inc. (NASDAQ:SRTA), filed a Form 4 on September 10, 2026, disclosing a share withholding transaction dated September 8, 2026, related to the vesting of restricted stock units.
Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc, filed a Form 4 on September 10, 2026, disclosing the disposition of 1,026 shares of common stock on September 8, 2026, to satisfy tax withholding obligations arising from the release of restricted stock units.
Aby J. Mathew, Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc, filed a Form 4 on September 10, 2026, disclosing a share withholding transaction dated September 8, 2026, related to the release of restricted stock units.
A Form 4 filed on September 10, 2026, disclosed that Matthew W. Calkins, CEO, President, and Director of Appian Corp (NASDAQ:APPN), sold a total of 45,000 shares of Class A Common Stock on September 8, 2026, under a pre-established Rule 10b5-1 trading plan.
Todd Berard, Chief Marketing Officer of BioLife Solutions Inc, filed a Form 4 on September 10, 2026, disclosing a disposition of 356 shares of common stock on September 8, 2026, to satisfy tax withholding obligations tied to the release of restricted stock units.